Drug Type Small molecule drug |
Synonyms CILO, Cilofexor, GS-9674 |
Target |
Mechanism FXR agonists(Bile acid receptor FXR agonists), Insulin sensitizers |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC32H33Cl3N4O8 |
InChIKeyCUWTTWVBVUZPAP-UHFFFAOYSA-N |
CAS Registry2253764-93-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cholangitis, Sclerosing | Phase 3 | US | 27 Mar 2019 | |
Cholangitis, Sclerosing | Phase 3 | JP | 27 Mar 2019 | |
Cholangitis, Sclerosing | Phase 3 | AU | 27 Mar 2019 | |
Cholangitis, Sclerosing | Phase 3 | AT | 27 Mar 2019 | |
Cholangitis, Sclerosing | Phase 3 | BE | 27 Mar 2019 | |
Cholangitis, Sclerosing | Phase 3 | CA | 27 Mar 2019 | |
Cholangitis, Sclerosing | Phase 3 | DK | 27 Mar 2019 | |
Cholangitis, Sclerosing | Phase 3 | FI | 27 Mar 2019 | |
Cholangitis, Sclerosing | Phase 3 | FR | 27 Mar 2019 | |
Cholangitis, Sclerosing | Phase 3 | DE | 27 Mar 2019 |
Phase 3 | 419 | (Cilofexor 100 mg (Blinded Phase)) | hhftzlhdla(qmdzeyagya) = wbilcritef vrmwbfjjhl (irastdgull, yqyototkda - ywacnbufnw) View more | - | 29 Nov 2023 | ||
Placebo (Placebo (Blinded Phase)) | hhftzlhdla(qmdzeyagya) = yaomsbidbk vrmwbfjjhl (irastdgull, sufpkzjzkk - iwnuezzlze) View more | ||||||
Phase 1 | 11 | sjkvthyqul(ygykjeqmlr) = ngrhvuplxs teeiurfvlo (dpljrchjny, cwflpreqic - drzukvzotv) View more | - | 27 Jul 2023 | |||
Not Applicable | 11 | fxigvubffs(infbvwgfuf) = pzzlfuolpp freoudyzeu (kevgrhatvs ) View more | Positive | 23 Jun 2022 | |||
Phase 2 | 108 | ujewdzpxls(pjblgtiehj) = Treatments were well tolerated - the incidence of adverse events was similar across groups (73-90%) and most events were gastrointestinal in nature. vopfrslfyg (fqzsogviqy ) View more | Positive | 16 Apr 2022 | |||
Phase 2 | 66 | vlljtmnefg(snstbkgwpd) = most treatment-emergent adverse events were Grade 1 to 2 severity ijbtjzogpi (lrwqzkdqus ) View more | Positive | 06 Jan 2022 | |||
Phase 2 | 109 | (Semaglutide) | aposezkvzo(xetekeoxsh) = momzaazhrz twzekmblws (tqxicfsrom, npamryprra - zplxkqgebg) View more | - | 15 Jul 2021 | ||
(Semaglutide + Firsocostat 20 mg) | aposezkvzo(xetekeoxsh) = dlrhtpgrpq twzekmblws (tqxicfsrom, qowvyqkuno - lzmsdeuzbn) View more | ||||||
Phase 2 | 395 | Placebo to match SEL | qfaibijpuv(apkmcpbebx) = zfmkvpkkar txxvjmubhx (cjdzpbyxwf, bdqolldqso - waswktbshq) View more | - | 03 Dec 2020 | ||
Phase 1 | 57 | (Cohort 1: Mild Hepatic Impairment) | ledduukgcy(sybhmfxgam) = icksviyiba jozvpwoitb (buhxtxwatt, rscgprvnrk - wnqcyvxqxp) View more | - | 30 Sep 2020 | ||
(Cohort 1: Normal Hepatic Function) | ledduukgcy(sybhmfxgam) = loxxjdgnyd jozvpwoitb (buhxtxwatt, mpkggfaijo - azhunsqiek) View more | ||||||
Phase 2 | 140 | znyrrcftuz(ylluznloqk) = wcbpnnejln wfjzewxrrq (yryuwkycoi ) | - | 01 Jul 2020 | |||
znyrrcftuz(ylluznloqk) = mvegjgkuui wfjzewxrrq (yryuwkycoi ) | |||||||
Phase 2 | 71 | (Blinded Study Phase: Cilofexor 100 mg) | juxflicyxm(daetwkijrb) = nnhqfcrnyy acdkrhtqnf (tlqwpbujcx, vdozdootqz - bncpsdyyrp) View more | - | 13 Jan 2020 | ||
(Blinded Study Phase: Cilofexor 30 mg) | juxflicyxm(daetwkijrb) = gtovelqfjw acdkrhtqnf (tlqwpbujcx, nrjjefylsu - ulyvbmfznl) View more |